Obagi Medical Products Study
Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, announced the publication of a study showing that the use of its Condition & Enhance System (also marketed as Nu-Derm), when combined with Botulinum Toxin Type A treatments (BOTOX(R)), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo. Obagi’s Condition & Enhance System is referred to as “a Hydroquinone Skin Care System Plus Tretinoin” in the report.
“I was pleased to have this study published in the Aesthetic Surgery Journal because many of my patients have aged skin that doesn’t always look markedly improved with injectables alone. Many practitioners are not aware of the potential benefits associated with incorporating this system with other non-invasive procedures in the practice,” said Joel Schlessinger, MD, board certified dermatologist from Omaha, Neb., President of LovelySkin, and lead investigator of the study. “This data clearly highlights the fact that by adding Condition & Enhance to injectable patients’ treatment regimen, patients are addressing multiple aspects of aging skin for optimal results. The results prove that, even in patients who have previously had BOTOX, there is room for improvement.”
The Condition & Enhance System was clinically proven to increase patient satisfaction: 82 percent of study participants had peers notice a positive change in overall facial appearance, as compared to 16 percent of study participants in the standard skincare group. Study participants also reported the following by the conclusion of the trial (120 days):
– 89 percent of patients were either Satisfied or Extremely Satisfied with their overall facial appearance, as compared to 12 percent of the standard skincare group
– 93 percent were Satisfied or Extremely Satisfied with the treatment regimen, as compared to 12 percent of the standard skincare group
– 100% of study participants using the Condition & Enhance System wished to continue treatment after the close of the study
Visit www.obagi.com for information.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment